| Peer-Reviewed

Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center

Received: 6 January 2022    Accepted: 4 February 2022    Published: 16 February 2022
Views:       Downloads:
Abstract

Introduction: Appearig at the end of 2019, an acute respiratory disease caused by a new coronavirus (SARS-CoV-2) quickly spread from China to all parts of the world. Cardiovascular disease, hypertension, diabetes, respiratory tract diseases, and cancer, among others, are poor predictive factors for SARS-CoV-2 infection. However, it is not yet well established to date that the human immunodeficiency virus type 1 (HIV-1) increases mortality from COVID-19. We decided to describe aspectsof COVID-19 in HIV infected patients, followed up at the Outpatient Treatment Centre (CTA) in Dakar-Fann. Methodology: This was a retrospective descriptive and analytical study of PLHIV over 15 years of age followed at the Outpatient Treatment Centre in Fann in whom the diagnosis of COVID-19 was made between July 2020 and September March 2021 by the polymerase chain reaction method in time real (RT-PCR). Results: A total of 22 PLWHA had COVID-19 with a predominance of women (15/22 or 68%). The median age was 47 years (33-85). The majority (91%) were infected with HIV-1. The mean last LTCD4 count in patients before COVID-19 diagnosis was 582 cells/mm3 [51-1415]. The last viral load before SARS-CoV2 infection was undetectable in 19 patients or 86%. One patient was in virological rebound with 353.158copies/ml. Two had no available viral load, one was profile 2 (HIV-2) and one double profile (HIV1+2). One among the patients was an active smoker. Comorbidities were found in 14 patients (64%) dominated by hypertension (7/14) and obesity/overweight (6/14). One case of hepatic cytolysis due to auto-immune disease was noted. The most frequent symptoms were headache, severe asthenia, fever, anosmia, breath shortness and cough. Anti-COVID-19 therapy was initiated following to the national protocol in addition to ART (8 on ATRIPLA, 4 TLD and 2 on ATZ/r and LPV/r). Half of the patients were treated in hospital (11/22, i.e., 50%), including one in intensive care, namely the one with a virological rebound. The case lethality rate was 9% (02/22). The two deaths involved patients over 65 years of age who did not receive any vaccine, one of whom suffered from an auto-immune disease with poor treatment observance. Conclusion: Most patients were virologically controlled with a good LTCD4 level > 582 cells/mm3. The comorbidities found were identical to those already described, proving once again that HIV is probably not a separate factor. However, good monitoring of co-morbidities, support for therapeutic compliance and vaccination should enable effective control of this pandemic in HIV patients.

Published in World Journal of Public Health (Volume 7, Issue 1)
DOI 10.11648/j.wjph.20220701.11
Page(s) 1-5
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

SARS-CoV2, HIV, Dakar, Senegal

References
[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. 2020; 382 (8): 727–733. [PMC free article] [PubMed] [Google Scholar].
[2] Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus. (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020; 25 (4): 2000058. [PMC free article] [PubMed] [Google Scholar].
[3] WHO. WHO coronavirus disease (COVID-19) dashboard. https://COVID19.who.int/. Accessed 19 novembre 2021.
[4] CDC. coronavirus disease 2019 (COVID-19). https://www.cdc. gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. Accessed 19 novembre 2021.
[5] WHO. Coronavirus disease (COVID-19) pandemic. https://www. who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 19novembre 2021.
[6] World Health Organization. 2020. Coronavirus disease (COVID-19): situation report-130, WHO [Google Scholar].
[7] Richardson S, Hirsch JS, Narasimhan M, et al.; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323: 2052–9.
[8] Grasselli Giacomo, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323 (16) 1574, doi: http://dx.doi.org/10.1001/jama.2020.5394DOI.org (Crossref) avril.
[9] Mehra MD, Mandeep R, et al. Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. N Engl J Med 2020; doi: http://dx.doi.org/10.1056/NEJMoa2007621p.NEJMoa2007621. DOI.org (Crossref) mai.
[10] Hu Ling, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis 2020; doi: http://dx.doi. org/10.1093/cid/ciaa539 p. ciaa539. DOI.org (Crossref) mai.
[11] Zheng Zhaohai, et al. Risk Factors of Critical & Mortal COVID-19 Cases: A Systematic Literature Review and Meta-Analysis. J Infect 2020; doi: http://dx.doi.org/10.1016/j.jinf.2020.04.021 p. S0163445320302346. DOI.org (Crossref) avril.
[12] Ministere de la sante et de l’action sociale: Point de Situation sur la COVID-19 disponible le 30 septembre 2021. Consulté le Sur URL: https://www.sante.gouv.sn.
[13] Conseil National de Lutte contre le sida /Senegal - Revue annuelle - février 2021. Consulté sur URL: https://www.cnls-senegal.org/wp-content/uploads/2001/01/cnls-rapport-annuel-2020.pdf.
[14] Valentina Iserniaa, Zelie Juliaa, Sylvie Le Gaca, Antoine Bachelarda, Roland Landmana, Sylvie Larivena, Véronique Jolya, Laurène Deconincka, Christophe Riouxa, Xavier Lescurea, Yazdan Yazdanpanaha, Jade Ghosna, SARS-COV-2 infection in 30 HIV-infected patients followed-up in a French University Hospital International Journal of Infectious Diseases 101 (2020) 49-51.
[15] Blanco Jose L, et al. COVID-19 in Patients with HIV: Clinical Case Series. Lancet HIV 2020; doi: http://dx.doi.org/10.1016/S2352-3018(20)30111-9 p. S2352301820301119. DOI.org (Crossref) avril.
[16] Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIVpositive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med 2020; doi: 10.7326/M20-3689. 10.
[17] Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: a systematic review. AIDS Behav 2020; 1–8. Mandeep.
[18] De Francesco D, Verboeket SO, Underwood J, et al. Patterns of co-occurring comorbidities in people living with HIV. Open Forum Infect Dis 2018; 5: ofy272.
[19] Härter G, Spinner CD, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020; 48: 681.
[20] Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis 2020; ciaa 579. 15.
[21] Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020; S2352-3018 (20 May 28): 30164–8, doi: http://dx.doi.org/10.1016/S2352-3018(20)30164-8.
[22] Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and HIV: a case series. Clin Infect Dis 2020; 71: 2021–2.
[23] Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med 2020; doi: 10.1111/hiv.1291.
[24] Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr 2020; doi: 10.1097/QAI.0000000000002423.
[25] Sigel K, Swartz T, Golden E, et al. COVID-19 and people with HIV infection: oOutcomes for hospitalized patients in New York City. Clin Infect Dis 2020; ciaa880.
[26] Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: where they come from. J Med Virol. 2020; 92 (5): 518–521. [PMC free article] [PubMed] [Google Scholar].
[27] Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020 Aug; 24 (8): 2244–2249. [PMC free article] [PubMed] [Google Scholar].
Cite This Article
  • APA Style

    Ngom Ndeye Fatou, Ndiaye Kine, Lawson AT Dela-dem, Faye Mame Awa, Faye Fulgence Abdou, et al. (2022). Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center. World Journal of Public Health, 7(1), 1-5. https://doi.org/10.11648/j.wjph.20220701.11

    Copy | Download

    ACS Style

    Ngom Ndeye Fatou; Ndiaye Kine; Lawson AT Dela-dem; Faye Mame Awa; Faye Fulgence Abdou, et al. Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center. World J. Public Health 2022, 7(1), 1-5. doi: 10.11648/j.wjph.20220701.11

    Copy | Download

    AMA Style

    Ngom Ndeye Fatou, Ndiaye Kine, Lawson AT Dela-dem, Faye Mame Awa, Faye Fulgence Abdou, et al. Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center. World J Public Health. 2022;7(1):1-5. doi: 10.11648/j.wjph.20220701.11

    Copy | Download

  • @article{10.11648/j.wjph.20220701.11,
      author = {Ngom Ndeye Fatou and Ndiaye Kine and Lawson AT Dela-dem and Faye Mame Awa and Faye Fulgence Abdou and Doutchi Mahamadou and Mboup Ahmadou and Diaw Abibatou and Gaye Assietou and Ndiaye Alassane and Gueye Mamadou and Ba Awa and Ka Ousseynou},
      title = {Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center},
      journal = {World Journal of Public Health},
      volume = {7},
      number = {1},
      pages = {1-5},
      doi = {10.11648/j.wjph.20220701.11},
      url = {https://doi.org/10.11648/j.wjph.20220701.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjph.20220701.11},
      abstract = {Introduction: Appearig at the end of 2019, an acute respiratory disease caused by a new coronavirus (SARS-CoV-2) quickly spread from China to all parts of the world. Cardiovascular disease, hypertension, diabetes, respiratory tract diseases, and cancer, among others, are poor predictive factors for SARS-CoV-2 infection. However, it is not yet well established to date that the human immunodeficiency virus type 1 (HIV-1) increases mortality from COVID-19. We decided to describe aspectsof COVID-19 in HIV infected patients, followed up at the Outpatient Treatment Centre (CTA) in Dakar-Fann. Methodology: This was a retrospective descriptive and analytical study of PLHIV over 15 years of age followed at the Outpatient Treatment Centre in Fann in whom the diagnosis of COVID-19 was made between July 2020 and September March 2021 by the polymerase chain reaction method in time real (RT-PCR). Results: A total of 22 PLWHA had COVID-19 with a predominance of women (15/22 or 68%). The median age was 47 years (33-85). The majority (91%) were infected with HIV-1. The mean last LTCD4 count in patients before COVID-19 diagnosis was 582 cells/mm3 [51-1415]. The last viral load before SARS-CoV2 infection was undetectable in 19 patients or 86%. One patient was in virological rebound with 353.158copies/ml. Two had no available viral load, one was profile 2 (HIV-2) and one double profile (HIV1+2). One among the patients was an active smoker. Comorbidities were found in 14 patients (64%) dominated by hypertension (7/14) and obesity/overweight (6/14). One case of hepatic cytolysis due to auto-immune disease was noted. The most frequent symptoms were headache, severe asthenia, fever, anosmia, breath shortness and cough. Anti-COVID-19 therapy was initiated following to the national protocol in addition to ART (8 on ATRIPLA, 4 TLD and 2 on ATZ/r and LPV/r). Half of the patients were treated in hospital (11/22, i.e., 50%), including one in intensive care, namely the one with a virological rebound. The case lethality rate was 9% (02/22). The two deaths involved patients over 65 years of age who did not receive any vaccine, one of whom suffered from an auto-immune disease with poor treatment observance. Conclusion: Most patients were virologically controlled with a good LTCD4 level > 582 cells/mm3. The comorbidities found were identical to those already described, proving once again that HIV is probably not a separate factor. However, good monitoring of co-morbidities, support for therapeutic compliance and vaccination should enable effective control of this pandemic in HIV patients.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Epidemiological, Clinical, Paraclinical and Evolutionary Aspects of SARS-CoV-2 Infection in 22 HIV-Infected Patients Followed at the Fann Outpatient Treatment Center
    AU  - Ngom Ndeye Fatou
    AU  - Ndiaye Kine
    AU  - Lawson AT Dela-dem
    AU  - Faye Mame Awa
    AU  - Faye Fulgence Abdou
    AU  - Doutchi Mahamadou
    AU  - Mboup Ahmadou
    AU  - Diaw Abibatou
    AU  - Gaye Assietou
    AU  - Ndiaye Alassane
    AU  - Gueye Mamadou
    AU  - Ba Awa
    AU  - Ka Ousseynou
    Y1  - 2022/02/16
    PY  - 2022
    N1  - https://doi.org/10.11648/j.wjph.20220701.11
    DO  - 10.11648/j.wjph.20220701.11
    T2  - World Journal of Public Health
    JF  - World Journal of Public Health
    JO  - World Journal of Public Health
    SP  - 1
    EP  - 5
    PB  - Science Publishing Group
    SN  - 2637-6059
    UR  - https://doi.org/10.11648/j.wjph.20220701.11
    AB  - Introduction: Appearig at the end of 2019, an acute respiratory disease caused by a new coronavirus (SARS-CoV-2) quickly spread from China to all parts of the world. Cardiovascular disease, hypertension, diabetes, respiratory tract diseases, and cancer, among others, are poor predictive factors for SARS-CoV-2 infection. However, it is not yet well established to date that the human immunodeficiency virus type 1 (HIV-1) increases mortality from COVID-19. We decided to describe aspectsof COVID-19 in HIV infected patients, followed up at the Outpatient Treatment Centre (CTA) in Dakar-Fann. Methodology: This was a retrospective descriptive and analytical study of PLHIV over 15 years of age followed at the Outpatient Treatment Centre in Fann in whom the diagnosis of COVID-19 was made between July 2020 and September March 2021 by the polymerase chain reaction method in time real (RT-PCR). Results: A total of 22 PLWHA had COVID-19 with a predominance of women (15/22 or 68%). The median age was 47 years (33-85). The majority (91%) were infected with HIV-1. The mean last LTCD4 count in patients before COVID-19 diagnosis was 582 cells/mm3 [51-1415]. The last viral load before SARS-CoV2 infection was undetectable in 19 patients or 86%. One patient was in virological rebound with 353.158copies/ml. Two had no available viral load, one was profile 2 (HIV-2) and one double profile (HIV1+2). One among the patients was an active smoker. Comorbidities were found in 14 patients (64%) dominated by hypertension (7/14) and obesity/overweight (6/14). One case of hepatic cytolysis due to auto-immune disease was noted. The most frequent symptoms were headache, severe asthenia, fever, anosmia, breath shortness and cough. Anti-COVID-19 therapy was initiated following to the national protocol in addition to ART (8 on ATRIPLA, 4 TLD and 2 on ATZ/r and LPV/r). Half of the patients were treated in hospital (11/22, i.e., 50%), including one in intensive care, namely the one with a virological rebound. The case lethality rate was 9% (02/22). The two deaths involved patients over 65 years of age who did not receive any vaccine, one of whom suffered from an auto-immune disease with poor treatment observance. Conclusion: Most patients were virologically controlled with a good LTCD4 level > 582 cells/mm3. The comorbidities found were identical to those already described, proving once again that HIV is probably not a separate factor. However, good monitoring of co-morbidities, support for therapeutic compliance and vaccination should enable effective control of this pandemic in HIV patients.
    VL  - 7
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Outpatient Treatment Center, Fann University Hospital, Dakar, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Faculty of Medicine, Cheikh Anta Diop de Dakar University, Dakar, Senegal

  • Faculty of Medicine, Cheikh Anta Diop de Dakar University, Dakar, Senegal

  • Outpatient Treatment Center, Fann University Hospital, Dakar, Senegal

  • Department of Community Health, University Alioune Diop, Bambey, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Clinic of Infectious Diseases, Tivaouane Hospital, Unit of Health and Sustainable Thies, Thies, Senegal

  • Outpatient Treatment Center, Fann University Hospital, Dakar, Senegal

  • Faculty of Health Science, Zinder University, Zinder, Niger

  • Sections